ClinicalTrials.gg
Not yet recruitingNCT07653451ESCC-PTUpdated Jun 17, 2026

Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer

A Phase 2/3 interventional study of Afatinib + Toripalimab and Dalpiciclib + Pyrotinib in Esophageal Squamous Cell Carcinoma, sponsored by Peking University Cancer Hospital & Institute. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Peking University Cancer Hospital & Institute · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing toripalimab in Esophageal Squamous Cell Carcinoma — 10 open to participants now, 11 under way, 4 of them phase 3. toripalimab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
9th of 18
90 · median 69
Started
2026
with 3 others
Phase 2/3
Only one
of the 18
Primary completion
2027-12
later than 4 of 10 live
Registered
17th of 18
by date
Lead sponsor
1 of 18
Peking University Cancer Hospital & Institute

Among the 18 studies testing toripalimab in Esophageal Squamous Cell Carcinoma, this one is the 9th largest by planned enrollment, is one of 4 that started in 2026, is the only one in phase 2/3, reaches primary completion later than 4 of the 10 other live ones, and was the 17th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

10 of the 18 studies testing toripalimab in Esophageal Squamous Cell Carcinoma are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing toripalimab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

This study is an open-label, biomarker-integrated umbrella trial designed to evaluate the clinical efficacy of molecular subtype- and genomic biomarker-guided precision therapies in patients with advanced esophageal cancer refractory to prior immunotherapy. Conducted in a two-step process, the study first enrolls patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed on prior immunotherapy, performing circulating tumor DNA (ctDNA) sequencing to stratify them into three distinct treatment cohorts, after which patients receive tailored combination regimens matched to their specific molecular profiling in the second step. Specifically, Cohort 1 includes patients with high EGFR expression or activation of EGFR-related signaling pathways, who will receive Afatinib (40 mg, p.o., Q.D.) combined with Toripalimab (240 mg, i.v., Q21D) in a 21-day treatment cycle, continuing until radiographic disease progression (PD), unacceptable toxicity, loss to follow-up, death, or other investigator-determined criteria for discontinuation, with a maximum toripalimab treatment duration of 24 months. Cohort 2 comprises patients harboring genomic alterations directly associated with cell cycle regulation or activation of cell cycle signaling pathways, who will be treated with Dalpiciclib (125 mg, p.o., Q.D. for 21 consecutive days followed by a 7-day off period in a 28-day cycle [Q4W]) combined with Pyrotinib maleate (320 mg, p.o., Q.D., administered within 30 minutes post-meal, Q4W) until disease progression, unacceptable toxicity, initiation of a new anti-tumor therapy, withdrawal of consent, or investigator's decision for treatment discontinuation. Cohort 3 includes patients with other molecular profiles who do not fit Cohorts 1 or 2, who will receive Camrelizumab (200 mg, i.v., Q3W) and Apatinib (250 mg, p.o., Q.D.), with clinical efficacy evaluations performed every 6 weeks, continuing until radiographic PD, unacceptable toxicity, death, or treatment discontinuation, whichever occurs first. The study aims to recruit an estimated maximum of 90 subjects, enrolling up to 30 subjects per cohort, with the final sample size dependent on the observed toxicities and the prevalence of each molecular cohort within the screened population.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Signed written from previous studies and age ≥18 years.
  2. or cytologically confirmed esophageal squamous cell carcinoma (ESCC).
  3. Locally advanced, unresectable, or ESCC that progressed on or after standard or later therapy containing immunotherapy (including but not limited to , PD-L1, CTLA-4 antibodies, or bispecific antibodies).
  4. At least one per 1.1.
  5. (ECOG) performance status of 0 or 1.
  6. Anticipated ≥12 weeks.
  7. Adequate organ and bone marrow function within 14 days prior to the first dose (without blood transfusion, EPO, G-CSF, or other hematologic supports), as defined by:

    • (ANC) ≥1.5×109/L
    • count ≥100×109/L
    • ≥9 g/dL (or ≥5.6 mmol/L)
    • Serum albumin >30 g/L
    • Serum creatinine ≤1.5× (Upper Limit of Normal) or calculated ≥60 mL/min (using the Cockcroft-Gault formula)
    • Total ≤1.5×ULN
    • and ALT ≤2.5×ULN (≤5.0×ULN for patients with documented liver metastases, provided total bilirubin is within normal limits)
    • (INR) or Prothrombin Time (PT) ≤1.5×ULN, and activated Partial Thromboplastin Time (aPTT) ≤1.5×ULN
  8. Female patients of (WOCBP) must have a negative pregnancy test within 7 days prior to the first dose. WOCBP and male patients with WOCBP partners must agree to use highly effective from signing the informed consent throughout the treatment period and for at least 6 months after the last dose. (Highly effective methods include oral/implanted hormonal contraceptives, intrauterine devices [IUDs], or barrier methods combined with spermicide. women aged >50 years must have been amenorrheic for ≥12 months to be considered postmenopausal).
  9. Required prior to the first dose of study treatment are as follows:

    • Systemic anticancer therapies (chemotherapy, targeted therapy, immunotherapy, biological therapy, or hormonal therapy) or participation in clinical trials: >4 weeks.
    • Systemic small-molecule targeted therapies: >2 weeks or 5 half-lives (whichever is longer).
    • Prior Chinese herbal medicine with anti-tumor activity: >2 weeks.
    • Prior major surgery or radiotherapy: >4 weeks (palliative radiotherapy for bone metastases: >2 weeks).

Exclusion Criteria:

Exclusion Criteria

  1. Currently receiving concurrent antitumor therapies (including chemotherapy, systemic therapy, immunotherapy, radiotherapy, or surgery) at the time of enrollment.
  2. History of other within the past 3 years (except for cured thyroid cancer, cervical carcinoma in situ, basal/squamous cell skin cancer, or other cured localized tumors with disease-free survival >3 years).
  3. Adverse events (AEs) from prior antitumor therapies that have not resolved to baseline or Grade ≤1 (excluding alopecia, Grade 2 anemia, or irreversible, clinically insignificant, asymptomatic laboratory abnormalities).
  4. Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose, or not fully recovered from surgical procedures; or plans for surgery during the study period.
  5. Active peripheral neuropathy (PN) or neurotoxicity ≥ Grade 2, history of Grade 3 neurotoxicity/PN, or prior permanent discontinuation of treatment due to neurotoxicity/PN.
  6. Active pneumonitis/interstitial lung disease (ILD), history of pulmonary radiation within 12 months prior to the first dose, or underlying pulmonary disease (e.g., ).
  7. Symptomatic or active central nervous system (CNS) metastases requiring intervention (including therapy with prednisone >10 mg/day or equivalents, or anticonvulsants) within 4 weeks prior to the first dose.
  8. Any other severe underlying medical condition, including but not limited to: uncontrolled diabetes, active infections, vaccination within 4 weeks, active peptic ulcer, uncontrolled epilepsy, cerebrovascular accident within 6 months, gastrointestinal bleeding within 3 months, or clinical signs of coagulopathy.
  9. Clinically significant cardiovascular disease, including:

    • (LVEF) ≤50% or below the institutional lower limit of normal (LLN) determined by echocardiography (ECHO) or MUGA scan (if ECHO is unavailable).
    • Heart failure classified as Class ≥III.
    • Uncontrolled hypertension (systolic BP ≥150 mmHg and/or diastolic BP ≥95 mmHg despite optimal medical therapy).
    • Prior or current cardiomyopathy.
    • Unstable angina, or myocardial infarction within 6 months.
    • Serious arrhythmia requiring medical intervention (excluding controlled atrial fibrillation or paroxysmal supraventricular tachycardia).
  10. ≥450 ms for males, or ≥470 ms for females (using Fridericia's formula), or history of congenital long QT syndrome.
  11. Dyspnea due to advanced malignancy complications or other diseases, requiring continuous supplemental oxygen therapy at rest.
  12. Any other severe psychiatric, psychological, familial, or geographical conditions that, in the investigator's opinion, could interfere with study compliance, protocol execution, follow-up, or place the patient at high risk of treatment-related complications.
  13. History of infection or positive HIV serology.
  14. Active viral or C (Note: Patients with HBV are eligible if HBV DNA is within the normal range/suppressed on antivirals; patients with positive antibody are eligible if HCV RNA is undetectable via PCR). Frequent viral load monitoring is mandatory.
  15. History of life-threatening allergies, known to any study drug components, recombinant proteins, or , or intolerance to EGFR antibodies or eribulin.
  16. Pregnant or lactating women.
  17. Any concurrent medical condition that, in the investigator's clinical judgment, could compromise protocol compliance.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    EGFR High Expression or Pathway Activation

    This treatment arm comprises patients with advanced esophageal squamous cell carcinoma (ESCC) who have progressed on prior immunotherapy and exhibit high EGFR expression or activation of EGFR-related signaling pathways determined by ctDNA sequencing.

    Drug: Afatinib + Toripalimab

  • Experimental
    Cell Cycle Pathway Alteration

    This treatment arm comprises patients with advanced ESCC refractory to prior immunotherapy harboring genomic alterations directly associated with cell cycle regulation or activation of cell cycle signaling pathways based on ctDNA profiling.

    Drug: Dalpiciclib + Pyrotinib

  • Experimental
    Other Molecular Subtypes

    This treatment arm comprises patients with advanced ESCC refractory to prior immunotherapy whose tumors present other molecular profiles not meeting the criteria for Cohorts 1 or 2.

    Drug: Camrelizumab + Apatinib

Interventions

  • DrugAfatinib + Toripalimab

    Drug pages: AfatinibStudies of AfatinibAfatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ToripalimabStudies of ToripalimabToripalimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients in this cohort will receive Afatinib at a dose of 40 mg orally (p.o.) once daily (Q.D.) combined with Toripalimab at a dose of 240 mg intravenously (i.v.) every 3 weeks (Q21D). Treatment will continue in 21-day cycles until radiographic disease progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met. Toripalimab administration is capped at a maximum duration of 24 months.

  • DrugDalpiciclib + Pyrotinib

    Drug pages: DalpiciclibStudies of DalpiciclibDalpiciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PyrotinibStudies of PyrotinibPyrotinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive Dalpiciclib at a dose of 125 mg p.o. Q.D. for 21 consecutive days followed by a 7-day off period in a 28-day cycle (Q4W), in combination with Pyrotinib maleate at a dose of 320 mg p.o. Q.D. administered within 30 minutes post-meal (Q4W). Treatment will continue until disease progression, unacceptable toxicity, initiation of a new anti-tumor therapy, or withdrawal of consent.

  • DrugCamrelizumab + Apatinib

    Drug pages: CamrelizumabStudies of CamrelizumabCamrelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ApatinibStudies of ApatinibApatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients in this cohort will receive a triple-combination therapy consisting of Camrelizumab (200 mg i.v. every 3 weeks \[Q3W\]), and Apatinib (250 mg p.o. Q.D.). Efficacy evaluations will be performed every 6 weeks. Treatment will continue until radiographic disease progression, unacceptable toxicity, death, or treatment discontinuation, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Progression-Free Survival (PFS) defined as the time from the first dose to the first documented disease progression per RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: 1 year

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) defined as the time from the first dose to death from any cause.

    Time frame: 1 year

  2. Objective Response Rate (ORR)

    Objective Response Rate (ORR) as assessed by RECIST v1.1

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Dec 2027, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 17, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07653451
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jun 17, 2026

Study contacts

zhihao Lu
Contact
pppeirain@126.com
010-88196561

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Afatinib · Toripalimab · Dalpiciclib · Pyrotinib · Camrelizumab · Apatinib

Start the discussion